Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12795239,Cmax,i.v. infusion produced a higher Cmax (0.96 +/- 0.26 mcg/ml vs. 0.36 +/- 0.19 mcg/ml) and a shorter Tmax (2.8 +/- 1.9 hr vs. 86 +/- 60 hr) when compared to i.m. injection.,"Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),[mcg] / [ml],0.96,118347,DB00092,Alefacept
,12795239,Cmax,i.v. infusion produced a higher Cmax (0.96 +/- 0.26 mcg/ml vs. 0.36 +/- 0.19 mcg/ml) and a shorter Tmax (2.8 +/- 1.9 hr vs. 86 +/- 60 hr) when compared to i.m. injection.,"Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),[mcg] / [ml],0.36,118348,DB00092,Alefacept
,12795239,Tmax,i.v. infusion produced a higher Cmax (0.96 +/- 0.26 mcg/ml vs. 0.36 +/- 0.19 mcg/ml) and a shorter Tmax (2.8 +/- 1.9 hr vs. 86 +/- 60 hr) when compared to i.m. injection.,"Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),h,2.8,118349,DB00092,Alefacept
,12795239,Tmax,i.v. infusion produced a higher Cmax (0.96 +/- 0.26 mcg/ml vs. 0.36 +/- 0.19 mcg/ml) and a shorter Tmax (2.8 +/- 1.9 hr vs. 86 +/- 60 hr) when compared to i.m. injection.,"Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),h,86,118350,DB00092,Alefacept
,12795239,relative bioavailability,"Based on AUC0-last and AUC0-infenity values, the relative bioavailability of i.m. to i.v. infusion was approximately 60%.","Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),%,60,118351,DB00092,Alefacept
,12795239,half-life,"After absorption from the i.m. injection was complete, the rate of alefacept elimination from the serum appeared consistent with the i.v. infusion half-life (approximately 12 days).","Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12795239/),d,12,118352,DB00092,Alefacept
